Squamous cell carcinoma antigen: prognostic significance and role in the monitoring of neoadjuvant chemotherapy response in cervical cancer.

Scambia, Giovanni; Panici, Pierluigi Benedetti; Foti, E; Amoroso, Mariangela; Salerno, G.; Ferrandina, Gabriella; Battaglia, Federica; Greggi, Stefano; Gaetano, Andrea De; Puglia, G

doi:10.1200/jco.1994.12.11.2309

Cited by 77 publications

(92 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Persistently elevated and/or increasing serum SCC concentrations after treatment suggest tumor persistence or progressive disease (387,398,399,408,(412)(413)(414)428 ). In 1 study, CEA and SCC marker concentrations measured 1 month after primary treatment with chemoradiation were better than pretreatment serum concentrations in predicting clinical outcome (413 ).…”

Section: Use Of Scc In Monitoring Response To Treatment and Early Detmentioning

confidence: 85%

“…Another group found that SCC and CA 125, in addition to stage, were significantly related to survival in the multivariate analysis of 142 patients with cervical cancer ranging from stage IA through IVB (385 ). It was concluded from a multivariate analysis of 102 women with locally advanced squamous cell cancer or adenocarcinoma of the cervix that an SCC concentration greater than 5 g/L was an independent predictor of response to neoadjuvant chemotherapy and poor survival (408 ). A pretreatment SCC concentration greater than 10 g/L (but not between 2 and 10 g/L) had a significant impact on survival in a multivariate analysis in 401 patients with stage I to IVA squamous cell cervical cancer, primarily treated with radiotherapy (399 ).…”

Section: Nacb Cervical Cancer Panel Recommendation 2: Serum Scc Concementioning

confidence: 99%

“…In patients with stage IB or IIA squamous cell cervical cancer, sensitivity of an elevated pretreatment concentration of SCC to detect lymph node metastases ranged from 60% to 87%, with specificity ranging from 41% to 91% (385,391,393,395,408,434 ). In a large series of 414 patients with early stage cervical cancer, elevated pretreatment SCC, large tumor size, and lymphovascular space involvement were independent risk factors for the presence of lymph node metastases (393 ).…”

Section: Prediction Of Lymph Node Metastases and Treatment Planningmentioning

confidence: 99%

See 2 more Smart Citations

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

et al. 2010

View full text Add to dashboard Cite

Background: Updated National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. Methods: Published reports relevant to use of tumor markers for 4 cancer sites—liver, bladder, cervical, and gastric—were critically reviewed. Results: α-Fetoprotein (AFP) may be used in conjunction with abdominal ultrasound for early detection of hepatocellular carcinoma (HCC) in patients with chronic hepatitis or cirrhosis associated with hepatitis B or C virus infection. AFP concentrations >200 μg/L in cirrhotic patients with typical hypervascular lesions >2 cm in size are consistent with HCC. After a diagnosis of HCC, posttreatment monitoring with AFP is recommended as an adjunct to imaging, especially in the absence of measurable disease. Although several urine markers have been proposed for bladder cancer, none at present can replace routine cystoscopy and cytology in the management of patients with this malignancy. Some may, however, be used as complementary adjuncts to direct more effective use of clinical procedures. Although carcinoembryonic antigen and CA 19-9 have been proposed for use gastric cancer and squamous cell carcinoma antigen for use in cervical cancer, none of these markers can currently be recommended for routine clinical use. Conclusions: Implementation of these recommendations should encourage optimal use of tumor markers for patients with liver, bladder, cervical, or gastric cancers.

show abstract

Section: Use Of Scc In Monitoring Response To Treatment and Early Detmentioning

confidence: 85%

Section: Nacb Cervical Cancer Panel Recommendation 2: Serum Scc Concementioning

confidence: 99%

Section: Prediction Of Lymph Node Metastases and Treatment Planningmentioning

confidence: 99%

See 1 more Smart Citation

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Pretreatment SCC levels correlate with cellular differentiation, tumour stage and volume, lymph node status and blood vessel invasion (Reynolds et al, 2005). However, there are conflicting reports on the prognostic significance of pretreatment SCC measurements (Scambia et al, 1994;Gaarenstroom et al, 1995;Duk et al, 1996;Ngan et al, 1996;Bolger et al, 1997;Hong et al 1998). In addition, there are no useful markers in cervical adenocarcinoma.…”

Section: Discussionmentioning

confidence: 99%

Can ABCF2 protein expression predict the prognosis of uterine cancer?

et al. 2008

View full text Add to dashboard Cite

Uterine cervical and endometrial cancers are common malignant solid neoplasms for which there are no useful prognostic markers. In this study, we evaluate the relationship between ATP-binding cassette superfamily F2 (ABCF2) expression and clinical factors including clinical stage, histologic type, grade and prognosis in uterine cervical and endometrial cancer. Two hundred and sixty seven cervical and 103 endometrial cancers were studied. ATP-binding cassette superfamily F2 cytoplasmic expression was detected by immunohistochemical staining and scored as positive or negative. Among cervical cancer cases, 149 (55.8%) expressed ABCF2. The overall survival was longer in ABCF2-negative than ABCF2-positive cases (P ¼ 0.0069). Statistically significant prognostic factors for survival were ABCF2 positivity (risk ratio (rr) ¼ 1.437), old age (rr ¼ 1.550) and advanced stage (rr ¼ 2.577). ATP-binding cassette superfamily F2 positivity was an independent prognostic factor by multivariate proportional hazard test (P ¼ 0.0002). Among endometrial cancer cases, 72 (69.9%) were cytoplasmic ABCF2 positive. However, there was no significant relationship between ABCF2 expression and age, clinical stage, histologic type, histologic grade, oestrogen receptor status or prognosis. ATP-binding cassette superfamily F2 expression may be a useful prognostic marker in cervical but not endometrial cancer. The role of ABCF2 protein may differ depending on the type of cancer.

show abstract

“…Lacking reliable clinical predictive factors, some authors tested chemotherapy resistance by assessing biochemical factors such as serum levels of squamous cell carcinoma antigen [12], microvessel density [6,7], oncogenes and tumor suppressor genes [13], and cyclooxygenase-2 [8]. Anemia is the most frequently observed hematological abnormality factor among cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Pretreatment serum hemoglobin level as a predictive factor of response to neoadjuvant chemotherapy in patients with locally advanced squamous cervical carcinoma: A preliminary report

Fuso

Mazzola

Marocco

et al. 2005

Gynecologic Oncology

View full text Add to dashboard Cite

Objective. The aim of this study was to evaluate the predictive value of pretreatment serum hemoglobin level (Hb) together with a series of clinical and pathological variables available before neoadjuvant chemotherapy in locally advanced squamous cervical cancer.Methods. The influence on response to neoadjuvant chemotherapy of a series of pretreatment clinico-pathological features: hemoglobin level at diagnosis, age, parity, menopausal status, body mass index, clinical stage, tumor diameter, and nuclear grading were analyzed on 73 patients with locally advanced cervical cancer treated with platinum-based neoadjuvant chemotherapy followed by radical surgery. The relationships between pretreatment variables and response to chemotherapy were assessed in univariate and multivariate settings. A univariate and multivariate logistic regression model was adapted to predict an ''optimal'' response (pathological complete response or more than 50% reduction in tumoral diameter) or ''sub-optimal'' response (<50% reduction in tumoral diameter).Results. Seventy-three patients-clinical stage: Ib2: 29 (39.7%) IIa: 22 (30.1%) IIb: 22 (30.1%)-received 3 cycles of platinum-based neoadjuvant chemotherapy followed by type III radical hysterectomy. A complete response to neoadjuvant chemotherapy was significantly associated with higher level of pretreatment hemoglobin (mean 14.0 mg/dl) compared to patients with !50% response (12.7 mg/dl) or <50% (11.9 mg/dl) ( P = 0.002). At multivariate analysis, Hb level was found to be the most powerful and significantly related factor to response to neoadjuvant chemotherapy. A hemoglobin threshold of 12 mg/dl was able to distinguish between patients-with !12 mg/dl-at higher probability to respond to neoadjuvant chemotherapy from the ones at lower probability (hemoglobin level under 12 mg/dl). Patients with a complete response to chemotherapy had a 100% survival compared to 93.1% and 53.8% for patients with responses !50% and <50% respectively ( P = 0.0001). Patients with a pretreatment hemoglobin level of !12 mg/dl showed a survival of 87% compared to 63% for patients with a lower hemoglobin level ( P = 0.008).Conclusions. Pretreatment Hb level showed a prognostic and independent predictive value for response to neoadjuvant chemotherapy in locally advanced cervical cancer. In our preliminary report, performed on a limited sample, a threshold of 12 mg/dl seems to be helpful to distinguish between ''optimal'' and ''non-optimal'' response. D

show abstract

Squamous cell carcinoma antigen: prognostic significance and role in the monitoring of neoadjuvant chemotherapy response in cervical cancer.

Abstract: Our data show that SCC assay may provide useful information to improve the prognostic characterization and disease monitoring of patients with locally advanced cervical cancer undergoing neoadjuvant chemotherapy.

Cited by 77 publications

References 19 publications

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

Can ABCF2 protein expression predict the prognosis of uterine cancer?

Pretreatment serum hemoglobin level as a predictive factor of response to neoadjuvant chemotherapy in patients with locally advanced squamous cervical carcinoma: A preliminary report

Contact Info

Product

Resources

About